| 0.0841 -0.025 (-22.84%) | 04-17 12:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.15  |
1-year : | 0.19 |
| Resists | First : | 0.13 |
Second : | 0.16 |
| Pivot price | 0.11 |
|||
| Supports | First : | 0.07 |
Second : | 0.06 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.12 |
| MA(100) : | 0.25 |
MA(250) : | 0.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 16 |
| RSI | RSI(14): 27.7 |
|||
| 52-week | High : | 1.29 | Low : | 0.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FOXO ] has closed below the lower bollinger band by 18.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ FOXO ] is to continue within current trading range. It is unclear right now based on current values. 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.11 - 0.11 | 0.11 - 0.11 |
| Low: | 0.07 - 0.07 | 0.07 - 0.07 |
| Close: | 0.08 - 0.08 | 0.08 - 0.09 |
FOXO Technologies Inc., a technology platform company, focuses on commercializing longevity science through products and services that serve the life insurance industry. The company is developing products and services that combine longevity science with life insurance to support the consumer health and wellness engagement, and to simplify the consumer underwriting journey. It offers FOXO Labs, a services platform that integrates saliva-based epigenetic biomarkers into accelerated underwriting protocols to improve the customer underwriting journey; and FOXO Life, an insurance products platform that offers proprietary life insurance products and third-party life insurance carrier products based on bundling longevity science with life insurance. The company was founded in 2019 and is based in Minneapolis, Minnesota.
Thu, 17 Apr 2025
FOXO Technologies Plans 1-for-10 Reverse Stock Split - MarketScreener
Thu, 17 Apr 2025
FOXO Technologies Announces Reverse Stock Split - TipRanks
Thu, 17 Apr 2025
FOXO TECHNOLOGIES INC. ANNOUNCES REVERSE STOCK SPLIT - GlobeNewswire
Thu, 17 Apr 2025
FOXO stock plunges to 52-week low, touches $0.1 - Investing.com
Thu, 17 Apr 2025
FOXO Technologies Files Annual Report with Concerns - TipRanks
Wed, 16 Apr 2025
FOXO Technologies Inc. Files 2024 Annual Report with Going Concern Disclosure - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.112e+007 (%) |
| Held by Institutions | 22.7 (%) |
| Shares Short | 162 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.33e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 675 % |
| Return on Equity (ttm) | -113.7 % |
| Qtrly Rev. Growth | 155000 % |
| Gross Profit (p.s.) | 66.98 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.12 |
| Dividend | 0 |
| Forward Dividend | 212640 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|